Abstract:Chronic myeloid leukemia (CML) is a hematological malignancy mainly caused by the Bcr-Abl oncogene that results from the reciprocal translocation between human chromosome 9 and 22, and occurs in more than 90% of CML cases. Bcr-Abl oncogene is also involved in tumorigenesis of other leukemia such as acute lymphoid leukemia (ALL). Although progress has been made in the understanding of signal transduction in Abl-mediated transformation, the molecular mechanisms underlying Abl-induced tumorigenesis are still not fully understood. It is well known that imatinib treatment can greatly suppress Bcr-Abl-mediated development of leukemia, but intracellular molecules induced by imatinib and their roles in the tumorigenesis remain largely to be determined. On the other hand, the majority of human transcripts lack protein-coding capacity, which are defined as noncoding RNAs (ncRNAs). Long noncoding RNAs (lncRNAs) play important roles in various vital biological processes. Notably, increasing number of lncRNAs have been linked to human diseases, including cancers. However, the role of lncRNAs in Bcr-Abl-induced leukemia remains largely unexplored. Here, we identified several imatinib-induced lncRNAs as critical regulator of Bcr-Abl-induced tumorigenesis. Most of these lncRNAs expressed in a very low levels in Bcr-Abl-positive cells from chronic myeloid leukemia patients. Interestingly, they could be significantly induced in Abl-positive leukemic cells treated by imatinib. Silencing these lncRNAs promoted survival of Abl-transformed human leukemic cells in experiments in vitro and xenografted tumor growth in mice, whereas ectopic expression of particular lncRNAs sensitized the cells to apoptosis and suppressed tumor growth. In concert, knockout of some murine lncRNAs in Abl-transformed cells accelerated cell survival and the development of leukemia in mice. Furthermore, some lncRNA deficient mice were generated, and we observed that knockout of particular murine lncRNAs facilitated Bcr-Abl-mediated primary bone marrow transformation. Moreover, animal leukemia model revealed that lncRNA deficiency promoted Abl-transformed cell survival and development of leukemia in mice. In summary, these findings unveil an inhibitory role of several critical lncRNAs in Abl-mediated cellular transformation, and provide new insights into molecular mechanisms underlying Abl-induced leukemogenesis. Citation Format: Jilong Chen, Yun Ma. Identification of imatinib-induced long noncoding RNAs involved in suppression of tumor growth mediated by bcr-abl oncogene [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl) nr LB037.

Additional File 6: of Induction of Apoptosis in Imatinib Sensitive and Resistant Chronic Myeloid Leukemia Cells by Efficient Disruption of Bcr-Abl Oncogene with Zinc Finger Nucleases

Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases

Forced Over-Expression of the Myeloid Zinc Finger Gene MZF-1 Inhibits Apoptosis and Promotes Oncogenesis in Interleukin-3-dependent FDCP.1 Cells.

The Induction of Dendritic Cells with Ifn-Alpha and Gm-Csf from Bone Marrow Mononuclear Cells from Patients with Chronic Myeloid Leukemia.

The Antiproliferation Effect of Berbamine on K562 Resistant Cells by Inhibiting NF‐κB Pathway

Extramedullary blast crisis of CD 34 + CD 38-leukemia stem cells in chronic myeloid leukemia resistant to tyrosine kinase inhibitors : a report of two cases

The Novel Anticancer Agent JNJ-26854165 is Active in Chronic Myeloid Leukemic Cells with Unmutated BCR/ABL and T315I Mutant BCR/ABL Through Promoting Proteosomal Degradation of BCR/ABL Proteins

Stromal Cells Attenuate the Cytotoxicity of Imatinib on Philadelphia Chromosome-Positive Leukemia Cells by Up-Regulating the VE-cadherin/β-catenin Signal

Single Nucleotide Polymorphisms in Apoptosis Pathway Are Associated with Response to Imatinib Therapy in Chronic Myeloid Leukemia

The molecular mechanisms underlying BCR/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy.

Roles of Phosphorylated P210bcr/abl and Hsp90 Protein in Apoptosis Induced by Berbamine in K562 Cells.

[Cytokine-Induced Killer Cells Induce Apoptosis of K562 Cells Expressed Bcr-Abl].

Small RNA activation of CDH13 expression overcome BCR-ABL1-independent imatinib-resistance and their signaling pathway studies in chronic myeloid leukemia

Abstract LB037: Identification of imatinib-induced long noncoding RNAs involved in suppression of tumor growth mediated by bcr-abl oncogene

Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia

Targeting BCL6 in gastrointestinal stromal tumor promotes p53-mediated apoptosis to enhance the antitumor activity of imatinib

Zinc as a potential regulator of the BCR-ABL oncogene in chronic myelocytic leukemia cells

The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF-κB Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells

BCL6 Enables Ph+ Acute Lymphoblastic Leukaemia Cells to Survive BCR–ABL1 Kinase Inhibition

Bone Marrow Stromal Cells Induced Activation of Nuclear Factor Κb Signaling Protects Non-Hodgkin’s B Lymphoma Cells from Apoptosis

Inhibition of apoptosis by downregulation of hBex1, a novel mechanism, contributes to the chemoresistance of Bcr/Abl+ leukemic cells.